Pitolisant for Prader-Willi syndrome in ongoing study
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an oral medication, pitolisant, in people with Prader-Willi syndrome who have already been in a pitolisant study. It aims to see if continuing treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in a previous study of the drug pitolisant and finished it.
- You are willing to use birth control during and for a short time after the study (if you could become pregnant or get someone pregnant).
- You are not breastfeeding or planning to breastfeed during the study.
- Your kidneys are working well enough (no dialysis needed).
- You do not have a high risk of suicide based on recent screenings or doctor's judgment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called CSTI-500 for people with Prader-Willi syndrome who are in the hyperphagia (constant hunger) phase. It aims to see if the drug can improve behavior and reduce overeating. You and your caregiver will need to visit the clinic regularly and answer questions about symptoms.
This study tests an experimental drug called BMB-101 to see if it can help reduce the constant hunger (hyperphagia) that is common in Prader-Willi syndrome. The trial will check how safe and effective the drug is, and if it works, it may offer a new treatment option.
This trial studies whether taking prebiotics and probiotics can help children with Prader-Willi syndrome manage obesity. It’s testing a gut-focused approach to weight control over the study period.
This study tests whether giving growth hormone to adults with Prader-Willi syndrome can improve their health and well-being. The goal is to see if the treatment is safe and helpful for adults with this condition.
This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.
This study follows people with Prader-Willi syndrome who are already taking or starting VYKAT XR, including those switching from an earlier version of the drug (DCCR). It aims to understand how the treatment works in everyday life.
Hear when a new Prader-Willi Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.